MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma

Chen, Di; Zhang, Rui; Huang, Xiaoming; Ji, Chunxia; Xia, Wei; Qi, Ying; Yang, Xinyu; Lin, Lishuang; Wang, Jing; Cheng, Haixia; Tang, Weijun; Yu, Jinhua; Hoon, Dave S. B.; Zhang, Jun; Gao, Xin; Yao, Yu

doi:10.1186/s40364-024-00560-6

Table 2 Univariate and multivariate cox regression analysis in subgroups from immunotherapy-treated cohort for OS and PFS

From: MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma

Factor	Univariate Cox regression		Multivariate Cox regression
Factor	HR (95% CI)	*P value*	HR (95% CI)	*P value*
OS for patients with high RIB (N=15)
Age (≤40 vs >40 )	0.87 (0.23-3.4)	0.85	/	/
Gender (Male vs Female)	1 (0.29-3.6)	0.98	/	/
Location (Non-frontal vs Frontal)	1 (0.31-3.3)	0.97	/	/
IDH1^wtTERT^mt (Yes vs No)	1.2 (0.35-3.9)	0.79	0.43 (0.093-2.01)	0.285
Patient (Recurrent vs Newly Diagnosed)	0.82 (0.25-2.7)	0.74	0.96 (0.268-3.41)	0.944
Treatment (DC Vaccine vs Placebo)	0.17 (0.04-0.68)	0.013	0.1 (0.018-0.58)	0.01
OS for patients with low RIB (N=16)
Age (≤40 vs >40 )	0.27 (0.058-1.3)	0.099	0.11 (0.016-0.77)	0.026
Gender (Male vs Female)	0.4 (0.12-1.3)	0.13	/	/
Location (Non-frontal vs Frontal)	0.43 (0.13-1.4)	0.16	/	/
IDH1^wtTERT^mt (Yes vs No)	1.7 (0.5-5.6)	0.41	1.33 (0.326-5.42)	0.692
Patient (Recurrent vs Newly Diagnosed)	0.65 (0.21-2.1)	0.47	0.26 (0.053-1.29)	0.099
Treatment (DC Vaccine vs Placebo)	0.67 (0.2-2.3)	0.51	0.84 (0.230-3.05)	0.787
PFS for patients with high RIB (N=15)
Age (≤40 vs >40 )	0.52 (0.14-1.9)	0.32	/	/
Gender (Male vs Female)	0.58 (0.18-1.8)	0.36	/	/
Location (Non-frontal vs Frontal)	0.91 (0.29-2.8)	0.86	/	/
IDH1^wtTERT^mt (Yes vs No)	0.78 (0.25-2.4)	0.67	0.36 (0.091-1.40)	0.14
Patient (Recurrent vs Newly Diagnosed)	0.88 (0.28-2.8)	0.83	1.16 (0.349-3.86)	0.808
Treatment (DC Vaccine vs Placebo)	0.17 (0.041-0.68)	0.013	0.1 (0.020-0.51)	0.005
PFS for patients with low RIB (N=16)
Age (≤40 vs >40 )	0.22 (0.047-1)	0.049	0.19 (0.033-1.1)	0.07
Gender (Male vs Female)	0.93 (0.33-2.6)	0.89	/	/
Location (Non-frontal vs Frontal)	0.4 (0.13-1.2)	0.1	0.3 (0.047-1.9)	0.205
IDH1^wtTERT^mt (Yes vs No)	1.4 (0.48-4.3)	0.52	1.25 (0.315-5.0)	0.749
Patient (Recurrent vs Newly Diagnosed)	1.5 (0.51-4.3)	0.47	0.6 (0.102-3.5)	0.572
Treatment (DC Vaccine vs Placebo)	1.7 (0.59-4.7)	0.34	2.83 (0.839-9.6)	0.094

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com

Biomarker Research

Contact us